Skip Navigation

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

 

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines & 3rd Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

Clinical Trials in Movement Disorders

Your participation will allow you to have firsthand experience with developing new medical treatments that may be beneficial to others. Current treatment methods for neurologic disorders are only available because of volunteer participants in clinical trials. Clinical trial information is excerpted from www.clinicaltrials.gov.

Parkinson's Disease and Related Disorders

A Clinical Study of NLY01 in Patients With Early Parkinson's Disease (NCT04154072)

Objective: Phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in subjects with early untreated Parkinson's disease 
Eligibility: Individuals 30 to 80 years old, with early-stage Parkinson’s disease, not on any current treatments
P.I.: Emile Moukheiber, M.D. Contact: Kori Ribb: 410-614-2216

XTRA PET for Cognitive Function in Parkinson’s (NA_00076249)

Objective: To understand the brain chemistry involved in cognitive function in Parkinson's disease patients, and how this affects the outcome of deep brain stimulation surgery
Eligibility: Parkinson's disease patients scheduled to undergo deep brain stimulation; Parkinson's disease patients not considering deep brain stimulation 
P.I.: Kelly Mills, M.D. Contact: Research Assistant: 410-955-6672

Rotigotine for Anxiety in Parkinson's (NA_00092051) 

Objective: Eight-week study of rotigotine for the treatment of anxiety disorders in Parkinson's disease
Eligibility: Individuals diagnosed with Parkinson's disease experiencing anxiety
P.I.: Gregory Pontone, M.D. Contact: Kate Perepezko: 410-614-1242 

APL-130277 for the Acute Treatment of OFF Episodes (NA_00086593) 

Objective: Evaluate APL-130277 (sublingual version of apomorphine hydrochloride) in treatment of sudden "off time" in Parkinson's disease
Eligibility: Individuals with Parkinson's disease taking levodopa and having at least 2 hours of "off time" daily
P.I.: George Ricaurte, M.D. Contact: Kori Ribb: 410-614-2216 

Evaluation of the Personal KinetiGraph (PKG) to improve insight into Parkinson’s disease symptoms

Objective: To understand the utility of the data of a wearable Personal KinetiGraph in the clinical management of Parkinson's disease in routine clinical care
Eligibility: Parkinson's disease patients in National Parkinson Foundation registry; responsiveness to dopaminergic medications; No deep brain stimulation/DUOPA (carbidopa and levodopa)
P.I.Kelly Mills, M.D. Contact: Emily Carman: 410-955-8909

Investigations of Neurovascular Abnormalities in the Olfactory Cortex Using Advanced MRI Technologies (IRB00141396) 

Objective: To investigate neurovascular abnormalities in the olfactory cortex using advanced MRI techniques
Eligibility: Parkinson's disease patients diagnosed for more than 3 years who are able to tolerate an MRI brain scan and undergo smell and memory identification tasks
P.I.: Jun Hua, Ph.D. Contact: Adrian Paez: 443-923-9551 

Udall Center Brain Donation Program (NA_00032761) 

Objective: Examine the pathological changes in the brain tissue of individuals diagnosed with Parkinson's disease or related disorders as compared to controls
Eligibility: Individuals diagnosed with Parkinson's disease or atypical Parkinson's disease and those without a neurological diagnosis
P.I.: Liana Rosenthal, M.D. Contact: Catherine Bakker: 410-616-2814 

Longitudinal Biomarkers of Individuals with Atypical Parkinsonism (IRB00062534)

Eligibility: Individuals with a diagnosis of multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS) or dementia with Lewy bodies (DLB); able to complete annual follow-up visits for 5+ years
P.I.Alex Pantelyat, M.D.  Contact: Vanessa Johnson: 410-616-2815

Biomarker Discovery and Validation in Progressive Supranuclear Palsy (DIVA-PSP) (IRB00173663)

Eligibility: Individuals with a diagnosis of Parkinson's disease or progressive supranuclear palsy (PSP), healthy controls; (caregiver/study partner also required for participation)
P.I.Alex Pantelyat, M.D. Contact: AJ Hall: 410-616-2813

Multimodal MRI in PSP (IRB00062534)

Eligibility: Individuals diagnosed w/ progressive supranuclear palsy (PSP-Richardson’s Syndrome, PSP-speech/language, PSP-corticobasal syndrome) or primary progressive aphasia (PPA); willingness/ability to complete MRI and lumbar puncture
P.I.Alex Pantelyat, M.D. Contact: Diane Lanham: 443-287-4156

Other Movement Disorders

Dystonia Coalition (NA_00074297)

Objective: Create an international repository to learn more about dystonia, treatment methods and patient response
Eligibility: Individuals over the age of 18 who have primary dystonia
P.I.Alex Pantelyat, M.D. Contact: Sydney Baybayan: 410-955-6692

General Characterization: Movement Disorders (NA_00055442) 

Objective: To study the genetic risk factors involved in movement disorders
Eligibility: Individuals with Parkinson's disease, atypical parkinsonism, dystonia, ataxia and Lewy body dementia
P.I.: Jeffrey Rothstein, M.D., Ph.D. Contact: Sonja Scholz

4RTNI-2 (NA_00130505)

Objective and Eligibility: Select individuals with corticobasal degeneration (CBD), progressive supranuclear palsy (PSP) or variant-progressive supranuclear palsy (vPSP); healthy controls, caregiver component  
P.I.: Alex Pantelyat, M.D. Contact: Diane Lanham: 443-287-4156

Parkinson's and Movement Disorder Digest

Twice a year, you'll receive trusted information from the experts at the Johns Hopkins Parkinson’s Disease and Movement Disorders Center delivered right to your inbox.

  
back to top button